We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

especially as income from Casgevy remains low in the near term, helping to diversify its commercial portfolio. Price Action: VRTX stock is down 0.46% at $411.47 at the last check on Tuesday.

Vertex (NASDAQ:VRTX) has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past (other than “dang, pain is a ...

Great. Good morning, everyone. Welcome. I'm Jess Fye, Biotech Analyst at J.P. Morgan. We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...